Market capitalization | $600.35m |
Enterprise Value | $784.66m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 29.87 |
P/S ratio (TTM) P/S ratio | 22.85 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $26.27m |
EBIT (operating result TTM) EBIT | $-287.92m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Phathom Pharmaceuticals Inc forecast:
7 Analysts have issued a Phathom Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 26 26 |
-
|
|
Gross Profit | 22 22 |
3,986%
3,986%
|
|
EBITDA | -287 -287 |
100%
100%
|
EBIT (Operating Income) EBIT | -288 -288 |
100%
100%
|
Net Profit | -339 -339 |
92%
92%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Head office | United States |
CEO | Terrie Curran |
Employees | 452 |
Founded | 2018 |
Website | www.phathompharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.